نتائج البحث - "Stratmann, Jan A."

المساهمون: Institut Català de la Salut, Liu G Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. Mazieres J Thoracic Oncology Department, Toulouse University Hospital, Toulouse, France. Stratmann J Department of Medicine II, Hematology/Oncology, University Hospital Frankfurt, Frankfurt, and National Network Genomic Medicine Lung Cancer, Cologne, Germany. Ignatius Ou SH Chao Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA, USA. Mok T State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong Special Administrative Region of China, China. Grizzard M Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA. Felip E Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Pulmons - Càncer - Tractament, Proteïnes quinases - Inhibidors - Ús terapèutic - Efectes secundaris, DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung, Other subheadings::Other subheadings::Other subheadings::/drug therapy, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors, Other subheadings::Other subheadings::Other subheadings::/adverse effects, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos

وصف الملف: application/pdf

العلاقة: Lung Cancer;191; https://doi.org/10.1016/j.lungcan.2024.107535Test; Liu G, Mazieres J, Stratmann J, Ignatius Ou SH, Mok T, Grizzard M, et al. A pragmatic guide for management of adverse events associated with lorlatinib. Lung Cancer. 2024 Mar 14;191:107535.; https://hdl.handle.net/11351/11297Test

الإتاحة: https://doi.org/10.1016/j.lungcan.2024.107535Test
https://hdl.handle.net/11351/11297Test

View record in BASE

4

دورية أكاديمية

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

المؤلفون: Michels, Sebastian, Vasyliv, I., Stratmann, Jan Alexander, Frank, Julia, Adams, Alexandra M., Massuti, Bartomeu, FELIP, ENRIQUETA

المساهمون: Institut Català de la Salut, Michels S Department I for Internal Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Lung Cancer Group Cologne, Cologne, Germany. Massutí B Department for Oncology, Alicante University Hospital-ISABIAL, Alicante, Spain. Vasyliv I University of Cologne, Faculty of Medicine and University Hospital of Colone, Department of Radiology and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany. Stratmann J Department of Hematology and Oncology, University Hospital of Frankfurt, Frankfurt am Main, Germany. Frank J, Adams A Faculty of Medicine and University Hospital of Cologne, Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany. Felip E Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Medicaments antineoplàstics - Ús terapèutic, Pulmons - Càncer - Tractament, Avaluació de resultats (Assistència sanitària), CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents, DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento

وصف الملف: application/pdf

العلاقة: ESMO Open;9(2); https://doi.org/10.1016/j.esmoop.2024.102237Test; Michels S, Massutí B, Vasyliv I, Stratmann J, Frank J, Adams A, et al. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial. ESMO Open. 2024 Feb;9(2):102237.; https://hdl.handle.net/11351/11105Test

الإتاحة: https://doi.org/10.1016/j.esmoop.2024.102237Test
https://hdl.handle.net/11351/11105Test

View record in BASE

النص الكامل